TIDMFUM
RNS Number : 4478N
Futura Medical PLC
01 June 2022
1 June 2022
Futura Medical plc
("Futura" or the "Company")
Notice of AGM and Availability of Annual Report
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, today announces its
Annual General Meeting ("AGM") will be held at 10:00 am on Tuesday
28 June 2022 at the offices of Liberum Capital Limited, Ropemaker
Place, 25 Ropemaker Street, London EC2Y 9LY.
Following the easing of coronavirus (COVID-19) restrictions in
the UK, the Board has made arrangements to enable shareholders to
attend the Annual General Meeting in person. However, in light of
the uncertainty as to any further COVID-19 measures that may be put
in place by the UK Government and bearing in mind the inherent risk
of large gatherings, the Company encourages shareholders to
consider submitting their voting instructions in advance by
appointing the Chairman of the meeting as their proxy, rather than
attending and voting on the day. This will ensure that votes are
registered in accordance with shareholders' wishes regardless of
any restrictions or disruption around the Annual General Meeting
and will also help protect the health and safety of shareholders,
directors and other necessary attendees. Depending on the public
health situation, we may impose additional procedures or
limitations on attendees beyond any described in this Notice of
Annual General Meeting.
If you wish to attend the meeting in person, please register
your interest, prior to 10:00 a.m. on 24 June 2022 at
investor.relations@futuramedical.com.
The Company requests that anyone who has recently tested
positive for COVID-19 and/or is showing symptoms, or anyone who
lives with somebody who has recently tested positive, does not
attend the meeting
Shareholders are asked to cast their vote as follows: (1)
casting your proxy vote online by logging on to
www.signalshares.com and following the instructions; or (2) in the
case of CREST members, by utilising the CREST electronic proxy
appointment service; or (3) requesting a hard copy form of proxy
directly from the registrars, Link Group. If you choose to attend
the Annual General Meeting in person instead of appointing the
Chairman of the meeting as proxy as we strongly recommend, you will
still be able to vote in person at the Annual General Meeting.
If you are not attending the Annual General Meeting in person,
your proxy vote will need to be lodged by 10:00 a.m. on 24 June
2022 as no online voting will take place in-real time during the
meeting itself.
The Company will operate an audio dial-in facility to allow
shareholders to listen to the business of the meeting: shareholders
will need to be confirmed as a shareholder or present a letter of
representation before details of how to access this facility are
released to them via email the morning of the meeting. You can
request access by emailing: investor.relations@futuramedical.com
prior to 10:00 a.m. on 24 June 2022.
This document should be read in conjunction with the Futura
Medical plc annual report and accounts. If you are in any doubt as
to the action you should take, you are recommended to seek your own
personal financial advice immediately from your stockbroker, bank
manager, solicitor, accountant or independent advisor, who, if you
are taking advice in the United Kingdom, is authorised pursuant to
the Financial Services and Markets Act 2000.
Shareholders will not get an opportunity to vote or ask
questions or any other participation during the call.
The situation in relation to COVID-19 is constantly evolving,
and the UK Government may change current restrictions or implement
further measures relating to the holding of Annual General Meetings
during the affected period. We will continue to monitor the
situation, and any changes to the Annual General Meeting will be
communicated to shareholders before the meeting through our website
and, where appropriate, by stock exchange announcement.
Annual Report
Futura's annual report and accounts for the year ended 31
December 2021 (the "Annual Report") is available to shareholders as
an electronic communication pursuant to the Companies Act 2006 and
is now available at the Company's website www.futuramedical.com,
along with the Notice of AGM.
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction ("ED") through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAZFLFXLELZBBB
(END) Dow Jones Newswires
June 01, 2022 02:01 ET (06:01 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2024 to Jun 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From Jun 2023 to Jun 2024